Business
Key Narmafotinib Patent Granted in the U.S.
Highlights The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent for the FAK inhibitor narmafotinibThe patent extends protection for narmafotinib to at least 2040 Melbourne, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has received formal notification from the US Patent and Trademark Office (USPTO) that a key patent titled A salt and crystal form o
About this update from Amplia Therapeutics Ltd.
[{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent for the FAK inhibitor narmafotinib","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"The patent extends protection for narmafotinib to at least 2040","length":63,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":202,"olType":false},{"type":"text","content":"Melbourne, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has received formal notification from the US Patent and Trademark Office (USPTO) that a key patent titled A salt and crystal form of a FAK Inhibitor has been granted. The Certificate of Grant follows on from the notification of allowance of the patent from the USPTO received in September1.","length":445,"tagName":"p"},{"type":"text","content":"This key patent protects the specific form of narmafotinib being developed clinically by the Company. The patent has already been granted in various important jurisdictions including Europe, Japan, India, Korea and Australia. Granting of this patent extends protection of narmafotinib out to a least 2040 in these jurisdictions. Protection in other regions is under review by the respective patent offices.","length":406,"tagName":"p"},{"type":"text","content":"Amplia CEO Dr Chris Burns says, “With the granting of this patent in the US and other key pharmaceutical markets, we are strengthening narmafotinib’s patent portfolio to protect and maximize the Company’s intellectual property for the long term.”","length":246,"tagName":"p"},{"type":"text","content":"About Amplia Therapeutics Limited","length":33,"tagName":"p"},{"type":"text","content":"Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.",...